biological source
mouse
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
114-6G6, monoclonal
form
liquid
contains
≤0.1% sodium azide as preservative
species reactivity
human
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, avoid repeated freeze/thaw cycles
isotype
IgG1
shipped in
wet ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... MMP14(4323)
General description
Purified mouse monoclonal antibody generated by immunizing mice with the specified immunogen and fusing splenocytes with NS1 mouse myeloma cells. Recognizes the ~66 kDa latent and the ~60 kDa active forms of MT1-MMP protein.
Recognizes the ~60-66 kDa MTI-MMP protein in HT-1080 cells and ConA-treated MD-MB-231 cells.
This Anti-MT1-MMP (Ab-3) Mouse mAb (114-6G6) is validated for use in Frozen Sections, Paraffin Sections, Immunoblotting, Immunocytochemistry, IP for the detection of MT1-MMP (Ab-3).
Immunogen
a synthetic peptide (REVPYAYIREGHEK) corresponding to amino acids 160-173 in the catalytic domain of human MT1-MMP
Application
Frozen Sections (not recommended)
Paraffin Sections (10 g/ml, Pronase<TMSYMBOL></TMSYMBOL> or heat pre-treatment required)
Immunoblotting (10 g/ml)
Immunocytochemistry (see application reference)
Immunoprecipitation (not recommended)
Packaging
Please refer to vial label for lot-specific concentration.
Physical form
In 100 mM sodium phosphate buffer, 0.1% BSA, pH 7.0.
Preparation Note
Following initial thaw, aliquot and freeze (-20°C).
Analysis Note
Negative Control
trpE (Ab-1) or untreated MD-MB-231 cells
trpE (Ab-1) or untreated MD-MB-231 cells
Positive Control
HT-1080 cells, ConA-treated MD-MB-231 cells, or breast carcinoma tissue
HT-1080 cells, ConA-treated MD-MB-231 cells, or breast carcinoma tissue
Other Notes
Does not cross-react with MT2-MMP or MT3-MMP. To induce MT1-MMP in MD-MB-231 cells, treat with 1-5 µg/ml ConA for 24-48 h. For best results with paraffin sections, fix with perioddate-lysine-4% paraformaldehyde. Antibody should be titrated for optimal results in individual systems.
Mattei, M.G., et al. 1997. Genomics40, 168.
Okada, A., et al. 1997. J. Cell. Biol.147, 67.
Okumura, Y., et al. 1997. FEBS Lett.402, 181.
Ueno, H., et al. 1997. Cancer Res.57, 2055.
Strongin, A.Y., et al. 1995. J. Biol. Chem.270, 5331.
Takino, T., et al. 1995. J. Biol. Chem.270, 23013.
Sato, H., et al. 1994. Nature370, 61.
Cottam, D.W. and Rees, R.C. 1993. Intl J. Oncol.2, 861.
Stetler-Stevenson, W.G., et al. 1993. FASEB J.7, 1434.
Fridman, R., et al. 1992. J. Biol. Chem.267, 15389.
Woessner, J.F. 1991. FASEB J.5, 2145.
Liotta, L.A. and Stetler-Stevenson, W.G. 1990. in Sem. Cancer Biol., ed. M.M. Gottesman. Vol. 1(2):99-106.
Goldberg, G.I., et al. 1989. PNAS86, 8207.
Okada, A., et al. 1997. J. Cell. Biol.147, 67.
Okumura, Y., et al. 1997. FEBS Lett.402, 181.
Ueno, H., et al. 1997. Cancer Res.57, 2055.
Strongin, A.Y., et al. 1995. J. Biol. Chem.270, 5331.
Takino, T., et al. 1995. J. Biol. Chem.270, 23013.
Sato, H., et al. 1994. Nature370, 61.
Cottam, D.W. and Rees, R.C. 1993. Intl J. Oncol.2, 861.
Stetler-Stevenson, W.G., et al. 1993. FASEB J.7, 1434.
Fridman, R., et al. 1992. J. Biol. Chem.267, 15389.
Woessner, J.F. 1991. FASEB J.5, 2145.
Liotta, L.A. and Stetler-Stevenson, W.G. 1990. in Sem. Cancer Biol., ed. M.M. Gottesman. Vol. 1(2):99-106.
Goldberg, G.I., et al. 1989. PNAS86, 8207.
Legal Information
Manufactured by Daiichi Fine Chemical Co., Ltd. Not available for sale in Japan.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
Still not finding the right product?
试用我们的 产品选型工具 工具缩小选择范围
存储类别
10 - Combustible liquids
wgk
WGK 1
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| IM42-100UG | 04055977220438 |